Posted by Michael Wonder on 27 Oct 2022
Health Canada approves Kerendia (finerenone) as an adjunct to standard of care therapy in adults with chronic kidney disease and type 2 diabetes
26 October 2022 - The approval is based on the results of the Phase 3 FIDELIO-DKD and FIGARO-DKD trial investigating the efficacy and safety of finerenone on kidney and cardiovascular outcomes in patients with chronic kidney disease associated with type 2 diabetes mellitus.
Bayer announced today that Health Canada approved finerenone, under the brand name Kerendia, as an adjunct to standard of care therapy in adults with chronic kidney disease and type 2 diabetes mellitus to reduce the risk of end-stage kidney disease and a sustained decrease in estimated glomerular filtration rate, cardiovascular death, non-fatal myocardial infarction and hospitalisation for heart failure.
